<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02024191</url>
  </required_header>
  <id_info>
    <org_study_id>031</org_study_id>
    <nct_id>NCT02024191</nct_id>
  </id_info>
  <brief_title>The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy</brief_title>
  <acronym>GELUPO</acronym>
  <official_title>The Role of Glutamine for Preventing Oxaliplatin-Induced Peripheral Neuropathy in Colorectal Cancer Patients. Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ankara Education and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ankara Education and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oxaliplatin is a chemotherapeutic agent, which is generally used in treatment of colorectal
      cancer. The dose limiting side effect of oxaliplatin is neurotoxicity. In this study we aimed
      to determine whether glutamine has role in prevention of oxaliplatin induced neuropathy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Our study population includes the colorectal cancer patient who is going to have mFOLFOX6
      (modified, Folinic acid 400 mg/m2 1 day, oxaliplatin 85 mg/m2 1 day, 5-fluorouracil l 400
      mg/m2 bolus 2400 mg/m2 continuous infusion 48 hours) regimen. We randomly assigned the
      patients into two groups. We administered glutamine at dose of 3x10 gr/day to one patient
      group concomitantly with mFOLFOX6 regimen and other group had no additional intervention. We
      performed questionnaire, neurological examination and EMG (Electromyography) before and after
      4th cycle of mFOLFOX6 regimen in both patient groups. We planned to compare the neurological
      signs, symptoms and EMG action potentials between mFOLFOX6+Glutamine and only mFOLFOX6 group.
      We aimed to search the role of glutamine as a prophylactic agent against oxaliplatin induced
      neuropathy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Electromyography parameters</measure>
    <time_frame>4 months interval</time_frame>
    <description>Electromyography action potential values will be compared between two patient groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological signs and symptoms</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Glutamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient group had 3x10 gr daily glutamine during first 4 cycles of mFOLFOX6 regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The group who had only mFOLFOX6 regimen, no additional intervention for neuropathy prophylaxis..</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Glutamine</intervention_name>
    <arm_group_label>Glutamine</arm_group_label>
    <other_name>Resource Glutamine 3x10 gr per day</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 20 - 65 years

          -  Operated and non operated colorectal cancer patients

          -  Patient administering mFOLFOX 6 ( Folinic acid 400 mg/m2 1 day, oxaliplatin 85 mg/m2 1
             day, 5-fluorouracil 400 mg/m2 bolus 2400 mg/m2 continuous infusion 48 hours)

        Exclusion Criteria:

          -  Patients who had chemotherapy in last 6 months

          -  Diabetes Mellitus

          -  Sensorimotor polyneuropathy

          -  Anemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ozan Yazici, MD</last_name>
    <phone>+90 312 5084610</phone>
    <email>drozanyazici@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nuriye Ozdemir, MD</last_name>
    <phone>+90 312 5084601</phone>
    <email>nyozdemir@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ankara Numune Education and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ozan Yazici, MD</last_name>
      <phone>+90 312 5084610</phone>
      <email>drozanyazici@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Nuriye Ozdemir, MD</last_name>
      <phone>+90 312 5084601</phone>
      <email>nyozdemir@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ozan Yazici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 25, 2013</study_first_submitted>
  <study_first_submitted_qc>December 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2013</study_first_posted>
  <last_update_submitted>December 30, 2013</last_update_submitted>
  <last_update_submitted_qc>December 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ankara Education and Research Hospital</investigator_affiliation>
    <investigator_full_name>Ozan Yazici</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>glutamine</keyword>
  <keyword>oxaliplatin</keyword>
  <keyword>peripheral neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

